---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041652"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:08:07.903873+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Processa Pharmaceuticals presents at Orphan Drugs Congress; no material new data disclosed

## Summary
- Dr. David Young, President of R&D, presented on Nov 16, 2023 at 2:40 PM ET at the 20th Orphan Drugs and Rare Diseases Global Congress in Boston.
- Presentation title: 'Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial'.
- Presentation furnished as Exhibit 99.1 but exhibit text not provided; no specific numbers, milestones, or guidance detailed in the 8-K.
- Company undertakes no obligation to update this Reg FD disclosure; no changes to business or financial condition reported.

## SEC filing metadata
- accession: 0001493152-23-041652
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/0001493152-23-041652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041652
- JSON: https://secwatch.observer/filing/0001493152-23-041652.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.